{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:53:50Z","timestamp":1767707630510},"reference-count":6,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T00:00:00Z","timestamp":1260144000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p><jats:bold>Background and purpose:\u2002<\/jats:bold> Botulinum toxin type A (BoNT\/A) is a highly effective and well\u2010tolerated treatment for focal dystonias. The BoNT\/A in Botox<jats:sup>\u00ae<\/jats:sup> and Dysport<jats:sup>\u00ae<\/jats:sup> is part of a high\u2010molecular\u2010weight complex that contains hemagglutinins and other non\u2010toxic proteins, whilst Xeomin<jats:sup>\u00ae<\/jats:sup> is a highly purified BoNT\/A free of such complexing proteins. In the largest controlled study of BoNT\/A published to date (Neurology 2005; 64: 1949), it was demonstrated that Xeomin<jats:sup>\u00ae<\/jats:sup> is non\u2010inferior to Botox<jats:sup>\u00ae<\/jats:sup> and has 1:1 efficacy in the treatment of cervical dystonia. A possible limitation of continued BoNT\/A treatment is antibody development. Based on its physiochemical properties and toxicological evidence, Xeomin<jats:sup>\u00ae<\/jats:sup> is expected to have a reduced incidence of non\u2010responders after long\u2010term treatment compared with other marketed BoNT\/A products.<\/jats:p><jats:p><jats:bold>Methods and results:\u2002<\/jats:bold> In our ongoing open\u2010label study, 100 patients suffering from cervical dystonia are continuously treated with Xeomin<jats:sup>\u00ae<\/jats:sup>; 50 patients were treated <jats:italic>de novo<\/jats:italic>, the remaining patients had been previously treated with Botox<jats:sup>\u00ae<\/jats:sup>, Dysport<jats:sup>\u00ae<\/jats:sup> or NeuroBloc<jats:sup>\u00ae<\/jats:sup>\/Myobloc<jats:sup>\u00ae<\/jats:sup>. All patients showed negative results in antibody testing at the beginning of Xeomin<jats:sup>\u00ae<\/jats:sup> treatment. During continuous treatment with Xeomin<jats:sup>\u00ae<\/jats:sup> up to 2\u2003years, patients continued to respond well to Xeomin<jats:sup>\u00ae<\/jats:sup> treatment.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> The treatment was well tolerated and no patient has developed neutralizing antibodies as measured using the sensitive mouse hemidiaphragma assay within these first 2\u2003years.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2009.02878.x","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T05:51:50Z","timestamp":1260251510000},"page":"6-10","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Xeomin<sup>\u00ae<\/sup> in the treatment of cervical dystonia"],"prefix":"10.1111","volume":"16","author":[{"given":"R.","family":"Benecke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/01421590701568262"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163767.99354.C3"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.020"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2009.01.017"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.28421-0"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20021"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2009.02878.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2009.02878.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:30:59Z","timestamp":1694604659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2009.02878.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":6,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1468-1331.2009.02878.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02878.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"2009-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}